Predict your next investment

CureApp company logo
MOBILE & TELECOMMUNICATIONS | Mobile Software & Services / Healthcare
cureapp.co.jp

See what CB Insights has to offer

Founded Year

2014

Stage

Series C | Alive

Total Raised

$38.53M

Last Raised

$20.28M | 2 yrs ago

About CureApp

CureApp is a digital health company that offers a horizontal spread of medical apps for treatment and management of a range of diseases, which allows patient treatment data to be obtained on a daily basis through mobile devices such as smartphones. This information is then analyzed using algorithms based on known medical information in order to provide personalized guidance for individual patients. Its apps exhibit therapeutic effects against nicotine addiction, NASH (non-alcoholic steatohepatitis remedy), diabetes, depression, and lung cancer.

CureApp Headquarter Location

Kodenmacho YS Building 4F 12-5 Nihonbashikodenmachō, Chūō-ku

Tokyo, 103-0001,

Japan

Latest CureApp News

CureApp's DTx app for hypertension found to reduce heart disease, stroke risks

Sep 17, 2021

The app provides personalised treatment guidance to users based on their BP record, habit logs and behavioural changes. Credit: CureApp A landmark clinical trial has found that a new digital therapeutic app for hypertension is effective in reducing the risks of cardiovascular and cerebrovascular diseases. Japanese medical technology startup CureApp collaborated with Jichi Medical University in the Tochigi Prefecture to conduct the third phase of the said clinical trial, which marks the world's first trial of a therapeutic app for hypertension. Findings were published in the European Heart Journal and presented to the European Society of Cardiology Congress last month. FINDINGS The trial, done from January to December last year, was performed on two groups of patients with essential hypertension: a control group that only received guidance on lifestyle changes based on the latest guidelines set by the Japanese Society of Hypertension and an intervention group that used the app, along with applying the same guidelines. The comparative study later found a 2.4 mmHg difference in the 24-hour systolic blood pressure between the groups based on ambulatory blood pressure monitoring. According to CureApp, this indicates a "significant hypotensive effect" in those users of the DTx app and a 10.7% reduced risk of developing cardiovascular and cerebrovascular diseases. In terms of morning home systolic BP – ​​an independent risk factor for cerebral apoplexy, there was a 4.3 mmHg difference between the groups or a reduction of 10 mmHg for the app users. WHY IT MATTERS CureApp developed the hypertension DTx app to assists patients in maintaining lifestyle improvements as part of their treatment. The app automatically delivers personalised treatment guidance to users, including advice on nutrition, exercise and sleep that are based on IoT blood pressure monitoring, lifestyle habit logs and notifications about behavioural changes. As it encourages awareness and helps patients to adopt sustainable lifestyle changes, the app provides a therapeutic effect that lowers their blood pressure, alleviating hypertension. CureApp also has a doctor's app where attending physicians can check on their patients remotely. Hypertension affects some 43 million people in Japan, according to the Japanese Society of Hypertension. It is also the highest risk factor for stroke and heart diseases, claiming the lives of an estimated 100,000 people each year. Government data previously reported that only 10 million Japanese people have received continuous treatment for the condition with 70% of patients failing to meet their target BPs or left untreated. Moreover, medical costs related to the condition went up to around 1.8 trillion yen (around US$16.5 billion). MARKET SNAPSHOT This year saw some companies developing digital therapeutics for depression. In February, Japanese firm Otsuka Pharmaceutical and Click Therapeutics from New York announced their remote clinical trial for a depression therapeutic app. Another New York-based company Happify Health was able to release what could be the first prescription DTx for treating major depressive disorder and generalised anxiety disorder. The Ensemble app helps patients acquire new skills and habits to manage their condition by using cognitive behavioural therapy, mindfulness and other techniques delivered through sequenced modules. CureApp has been working on some DTx apps over the past years. In August last year, it got regulatory approval from the Japanese government to market its CureApp SC , a prescription nicotine addiction treatment app and carbon monoxide checker. Some DTx apps under wraps include the NASH (nonalcoholic steatohepatitis) therapeutic app; the alcohol dependency therapeutic app; and the cancer patient support therapeutic app. According to Valuates Reports, the global market for digital therapeutics may reach a value of $13.8 billion by 2027 from $2.9 billion in 2019, growing at a 20.5% CAGR. Tags:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CureApp

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CureApp is included in 6 Expert Collections, including Digital Health.

D

Digital Health

11,686 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

M

Mental Health/Wellness Tech

964 items

This collection includes companies applying technology to problems of emotional, psychological, and social well-being. Examples include companies working in areas such as substance abuse, eating disorders, stress reduction, depression, PTSD, and anxiety.

D

Digital Health 150

300 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

M

Medical Devices

7,884 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

D

Diabetes

1,750 items

CureApp Patents

CureApp has filed 6 patents.

The 3 most popular patent topics include:

  • Psychiatric diagnosis
  • Cognitive behavioral therapy
  • Stimulants
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/20/2017

2/16/2021

Psychiatric diagnosis, Cognitive behavioral therapy, Stimulants, Smoking, Substance dependence

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/20/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

2/16/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Psychiatric diagnosis, Cognitive behavioral therapy, Stimulants, Smoking, Substance dependence

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CureApp Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CureApp Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.